ASCO 2021: Renal cancer roundup

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021

UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma